1. Mcl‐1 targeting could be an intriguing perspective to cure cancer
   Anna De Blasio et al, 2018, Journal of Cellular Physiology CrossRef
2. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells
   Maria T. Löblein et al, 2021, International Journal of Molecular Sciences CrossRef
3. Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
   Valéria Tavares et al, 2024, International Journal of Molecular Sciences CrossRef
4. Gentisyl Alcohol Inhibits Proliferation and Induces Apoptosis via Mitochondrial Dysfunction and Regulation of MAPK and PI3K/AKT Pathways in Epithelial Ovarian Cancer Cells
   Jiyeon Ham et al, 2019, Marine Drugs CrossRef
5. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway
   Hiroaki Yasui et al, 2020, Clinical & Experimental Metastasis CrossRef
6. Anticancer and Biological Effects of Some Natural Compounds and Theoretical Investigation of them Against RdRP of SARS-COV-2: In Silico and In Vitro Studies
   Jing Zhang et al, 2023, Molecular Biotechnology CrossRef
7. Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
   Soozana Puvanenthiran et al, 2018, Oncotarget CrossRef
8. Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety
   Halyna Kuznietsova et al, 2020, Journal of Drug Targeting CrossRef
9. LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465
   Hui Zhao et al, 2020, The Journal of Biochemistry CrossRef
10. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
    Aryan Stanley et al, 2017, Scientific Reports CrossRef
11. Expression of HER2 and EGFR Proteins in Advanced Stage High-grade Serous Ovarian Tumors Show Mutual Exclusivity
    Julian Crasta et al, 2021, International Journal of Gynecological Pathology CrossRef
12. Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile
    Fan Wang et al, 2017, Oncotarget CrossRef
13. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells
    Alexandra Kollara et al, 2023, Cellular Signalling CrossRef
14. LncRNA TP73‑AS1 predicts poor prognosis and promotes cell proliferation in ovarian cancer via cell cycle and apoptosis regulation
    Xiuyun Li et al, 2018, Molecular Medicine Reports CrossRef
15. Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells
    Ni Sima et al, 2018, Translational Oncology CrossRef
16. In vitro modelling of the physiological and diseased female reproductive system
    Anna Stejskalová et al, 2021, Acta Biomaterialia CrossRef
17. Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer
    Shanshan Wang et al, 2019, The International Journal of Biochemistry & Cell Biology CrossRef
18. In silico identification of potent small molecule inhibitors targeting epidermal growth factor receptor 1
    Zheng Shi et al, 2018, Journal of Cancer Research and Therapeutics CrossRef
19. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies
    F. Sanarica et al, 2019, Pharmacological Research CrossRef
20. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
    Ying Wei et al, 2023, Molecular Therapy - Oncolytics CrossRef
21. Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer
    Xiaoli Xu et al, 2018, Oncology Letters CrossRef
22. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
    Karolin Ebert et al, 2020, BMC Cancer CrossRef
23. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth
    Patrick M. Reeves et al, 2017, Anti-Cancer Drugs CrossRef
24. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer
    Gustavo A. Arias-Pinilla et al, 2018, Oncotarget CrossRef